| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Protein NUT (Nuclear protein in Tis) |
| Entrez GeneID | 256646 |
| WB Predicted band size | Calculated MW: 120 kDa; Observed MW: 63 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from human NUT. at AA range: 1082-1131 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于NUT抗体的参考文献及其摘要内容的简要概述：
1. **《NUT midline carcinomas: a diagnostic challenge》**
*作者：French CA (2014)*
摘要：该文献系统阐述了NUT中线癌(NMC)的临床与病理特征，重点讨论了NUT抗体(如C52抗体)在诊断中的核心作用，指出其作为NMC特异性标志物的高敏感性和特异性，并强调免疫组化检测NUT蛋白在鉴别未分化肿瘤中的重要性。
2. **《Detection of NUT rearrangement by FISH and immunohistochemistry in poorly differentiated sinonasal neoplasms》**
*作者：Bishop JA et al. (2013)*
摘要：研究通过FISH和免疫组化(使用NUT单克隆抗体)对比分析鼻腔鼻窦低分化肿瘤，证实NUT抗体免疫组化检测与基因检测结果高度一致，建议将其作为快速筛查NUT基因重排相关肿瘤的首选方法。
3. **《NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetic Signature》**
*作者：Agaimy A et al. (2021)*
摘要：该研究全面总结NUT癌的分子机制，强调NUT抗体的临床应用价值，指出其在区分其他小圆细胞肿瘤(如尤文肉瘤)中的特异性，并建议结合分子检测提高诊断准确性。
*注：以上文献可通过PubMed或专业病理学期刊数据库检索原文。经典研究多发表于《American Journal of Surgical Pathology》《Modern Pathology》等期刊。*
**Background of NUT Antibody**
The NUT (nuclear protein in testis) antibody is a critical diagnostic tool for identifying NUT midline carcinoma (NMC), a rare and aggressive cancer defined by rearrangements of the *NUTM1* (NUT carcinoma family member 1) gene. Initially discovered in 2003. *NUTM1* fusions—most commonly *BRD4-NUTM1* or *BRD3-NUTM1*—drive oncogenesis by forming chromatin-regulating complexes that block epithelial differentiation and sustain proliferation.
NUT antibodies specifically target the NUT protein, enabling immunohistochemical (IHC) detection of NMC, which often arises in midline structures (e.g., head, neck, thorax). Historically misclassified due to its undifferentiated morphology, NMC is now reliably diagnosed using NUT IHC, which shows >90% specificity and sensitivity. This has revolutionized its recognition among poorly differentiated carcinomas.
Clinically, NMC affects all ages but predominates in adolescents and young adults. Prognosis remains poor (median survival: ~6 months), with resistance to conventional therapies. However, NUT antibody-based diagnostics have spurred research into targeted therapies, such as BET inhibitors, aiming to disrupt oncogenic BRD-NUT interactions.
In summary, the NUT antibody is indispensable for diagnosing NMC, a disease emblematic of fusion-driven oncogenesis, while also guiding emerging precision oncology strategies.
×
